AU2018253960A1 - Coversin for the treatment of cicatrising eye inflammatory disorders - Google Patents

Coversin for the treatment of cicatrising eye inflammatory disorders Download PDF

Info

Publication number
AU2018253960A1
AU2018253960A1 AU2018253960A AU2018253960A AU2018253960A1 AU 2018253960 A1 AU2018253960 A1 AU 2018253960A1 AU 2018253960 A AU2018253960 A AU 2018253960A AU 2018253960 A AU2018253960 A AU 2018253960A AU 2018253960 A1 AU2018253960 A1 AU 2018253960A1
Authority
AU
Australia
Prior art keywords
seq
coversin
protein
complement
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018253960A
Other languages
English (en)
Inventor
Wynne H Weston-Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1706406.4A external-priority patent/GB201706406D0/en
Priority claimed from GBGB1706398.3A external-priority patent/GB201706398D0/en
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of AU2018253960A1 publication Critical patent/AU2018253960A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2018253960A 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders Abandoned AU2018253960A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706398.3 2017-04-21
GBGB1706398.3A GB201706398D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706406.4 2017-04-21
PCT/EP2018/060239 WO2018193120A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders

Publications (1)

Publication Number Publication Date
AU2018253960A1 true AU2018253960A1 (en) 2019-10-31

Family

ID=62028030

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018253960A Abandoned AU2018253960A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders

Country Status (8)

Country Link
US (1) US20210113658A1 (https=)
EP (1) EP3612206A1 (https=)
JP (2) JP7153669B2 (https=)
KR (1) KR20190138650A (https=)
CN (1) CN110831617A (https=)
AU (1) AU2018253960A1 (https=)
CA (1) CA3060331A1 (https=)
WO (1) WO2018193120A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2945433T3 (es) 2017-04-21 2023-07-03 Volution Immuno Pharmaceuticals Sa Coversina para el tratamiento de enfermedades ampollares autoinmunes
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2023503776A (ja) 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
EP4527584A4 (en) 2022-05-18 2025-08-20 Asahi Chemical Ind PROCESS FOR PRODUCING A RESIN COMPOSITION
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
PL2061501T3 (pl) * 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
JP2010521194A (ja) * 2007-03-22 2010-06-24 ノバルティス アーゲー Ｃ５抗原およびその使用
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2011056972A2 (en) * 2009-11-04 2011-05-12 Case Western Reserve University Compositions and methods of treating a t cell mediated disorder
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
CN103796667A (zh) * 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
WO2015134673A1 (en) * 2014-03-04 2015-09-11 The Trustees Of Columbia University In The City Of New York Method for treating ocular inflammation
GB201410031D0 (en) * 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3250230B9 (en) * 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
ES2945433T3 (es) 2017-04-21 2023-07-03 Volution Immuno Pharmaceuticals Sa Coversina para el tratamiento de enfermedades ampollares autoinmunes
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment

Also Published As

Publication number Publication date
JP2020517643A (ja) 2020-06-18
JP7153669B2 (ja) 2022-10-14
CA3060331A1 (en) 2018-10-25
JP2022188170A (ja) 2022-12-20
KR20190138650A (ko) 2019-12-13
EP3612206A1 (en) 2020-02-26
US20210113658A1 (en) 2021-04-22
WO2018193120A1 (en) 2018-10-25
CN110831617A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
US20210113658A1 (en) Coversin for the treatment of cicatrising eye inflammatory disorders
JP5439652B2 (ja) 眼の表面の潤滑性の治療的調節
Yang et al. IFN-γ facilitates corneal epithelial cell pyroptosis through the JAK2/STAT1 pathway in dry eye
US20240009270A1 (en) Coversin for the treatment of autoimmune blistering diseases
Liu et al. N-acetylcysteine alleviates ocular surface damage in STZ-induced diabetic mice by inhibiting the ROS/NLRP3/Caspase-1/IL-1β signaling pathway
Martin et al. Palate lung nasal clone (PLUNC), a novel protein of the tear film: three-dimensional structure, immune activation, and involvement in dry eye disease (DED)
Swamynathan et al. Corneal expression of SLURP-1 by age, sex, genetic strain, and ocular surface health
JP2023550661A (ja) ドライアイ治療用薬の調製におけるｐ５５ｐｉｋ阻害剤の応用
JP7603612B2 (ja) 治療法
JP6087429B2 (ja) 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途
EP4003396B1 (en) Tsg6 polypeptide fragment for dry eye disease
JP2021532121A (ja) 眼を治療するための組成物及び方法
Bedei et al. Real-world treatment outcomes of an artificial tear containing arabinogalactan, hyaluronic acid and trehalose among subjects with dry eye
TW202506704A (zh) 具有改善乾眼症活性的新型胜肽及包括其之藥物組合物
WO2025062470A1 (en) Compositions for the treatment of dry eye, conjunctivitis and wound healing
JP2016210773A (ja) 人工涙液の組成物

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted